Oncology

We are proud to be making a profound difference in the lives of people with cancer, by proving oncology treatments on the WHO Essential Medicines List.

ALOXI® is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. It may be used in paediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with moderately or highly emetogenic cancer chemotherapy. Aloxi is also indicated for prevention of post-operative nausea and vomiting for up to 24 hrs following surgery.

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country 

AKYNZEO®  is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country. 

ANAMORELIN® is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis. 

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country. 

TRUSELTIQ® (infigratinib) capsules 25mg/100mg is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. TRUSELTIQ®  is a pipeline therapy which has already been approved for 2nd Line with Phase 3 Trials and is currently under investigation as a potential first-line treatment for individuals with Adjuvant Urothelial Cancer in Australia.

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country.